No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Established in 2004 and headquartered in Shanghai, People's Republic of China, MicroPort NeuroTech Limited is dedicated to the research, development, manufacturing, and global commercialization of neuro-interventional medical devices. The company's diverse product portfolio addresses various cerebrovascular conditions. For treating hemorrhagic stroke, it offers the NUMEN coil embolization system, the NUMEN FR coil detachment system, the Tubridge flow-diverting stent, the Willis intracranial stent graft system, and the Rebridge intracranial visualized stent. Additionally, MicroPort NeuroTech supplies the APOLLO intracranial arterial stent system for intracranial atherosclerotic disease, as well as the Bridge rapamycin target eluting vertebral artery stent system specifically designed for cerebral atherosclerotic stenosis. To address acute ischemic stroke, the company provides the Neurohawk stent thrombectomy device and the Tigertriever adjustable stent retriever.
www.microportneurosci.comNo one on the platform currently holds 2172.HK.
No tracked institution reports a position in 2172.HK as of their last filing.
No one on the platform has traded 2172.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 17.5% | — | — | — | ||
| Rev. Growth % | 1.1% | 28.3% | ||||
| Profit Margin % | 23.3% | 16.2% | ||||
| Free Cash Flow Margin % | 20.0% | 21.4% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $915M | +10.3% | $0.44 | $0.44–$0.44 | — | 1 |
| 2027 | $1.1B | +15.4% | $0.50 | $0.50–$0.50 | — | 1 |
| 2028 | $1.0B | -2.0% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $2.09 |
| -1.18% |
| $5.6B |
| — |
| 2190.HKZylox-Tonbridge Medical Technology Co., Ltd. | $20.44 | -1.35% | $6.4B | — |
| 2192.HKMedlive Technology Co., Ltd. | $6.80 | -1.87% | $5.0B | — |
Source: Financial Modeling Prep · peers by sector/industry